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Introduction {#sec1}
============

Kidney podocytes are terminally differentiated glomerular epithelial cells unable to self-renew due to their inability to proliferate ([@bib31], [@bib66]), and replacement following loss is dependent on local kidney progenitors ([@bib53], [@bib32], [@bib57]). Glomerular parietal epithelial cells (PECs) ([@bib51], [@bib69], [@bib14], [@bib30], [@bib33]) and cells of renin lineage (CoRL) ([@bib47], [@bib48], [@bib35]) are considered likely adult podocyte progenitors. CoRL serve as progenitors for several kidney cell types ([@bib55]), including podocytes ([@bib19], [@bib47], [@bib48], [@bib49], [@bib56], [@bib35]), PECs ([@bib47], [@bib14]), mesangial cells ([@bib61], [@bib57]), and pericytes ([@bib59], [@bib49]). RAAS inhibition augments the CoRL reservoir in the juxta-glomerular compartment (JGC) through proliferation, enhances migration to the glomerulus, and increases transdifferentiation toward a podocyte fate ([@bib35]). CoRL and podocytes derive from mesenchymal origins ([@bib9], [@bib39], [@bib36], [@bib65]). CoRL maintain mesenchymal characteristics, whereas adult podocytes exhibit epithelial characteristics ([@bib16]). Therefore, for CoRL to serve as podocyte progenitors, they must undergo changes resembling a mesenchymal-to-epithelial transition (MET).

The transcription factor Wilms\' tumor suppressor protein 1 (WT1) is required for podocyte development and homeostasis ([@bib25]). Missense mutations and conditionally deleting WT1 from podocytes leads to glomerular scarring in humans and mice ([@bib45], [@bib17], [@bib7]). WT1 is closely linked to the mesenchymal-epithelial balance in development and disease ([@bib41]), and the homeostasis of different cell types ([@bib43]), including the plasticity and cell fate of certain cells ([@bib26], [@bib67]). WT1 drives MET at the start of nephron development ([@bib15], [@bib3]), although in the developing epicardium, WT1 controls the reverse, i.e., epithelial-to-mesenchymal transition ([@bib38]). WT1 enhances proliferation and migration in certain cell types in a context-dependent manner ([@bib63], [@bib5], [@bib20]). Finally, WT1 and renin co-localize in a fraction of cells in the afferent arterioles. Moreover, WT1 (−KTS) can negatively modulate renin gene transcription through interaction at a binding site within the renin enhancer ([@bib58]).

These reports provided the rationale to test the hypothesis that WT1 is required for CoRL proliferation, migration, and transdifferentiation toward a podocyte fate in the context of podocyte depletion.

Results {#sec2}
=======

WT1 Expression Increases in Renin-Stained Cells Following Podocyte Depletion in Mice and Humans {#sec2.1}
-----------------------------------------------------------------------------------------------

We began by measuring the temporal expression of WT1 in renin-stained cells in the JGC in *RenWt1*^*+/+*^ mice following podocyte depletion induced by the administration of a cytopathic anti-podocyte antibody. Following podocyte depletion, the percentage of renin cells co-staining for WT1 increased as follows ([Figures 1](#fig1){ref-type="fig"}A--1F): from a baseline to D3 of FSGS (6.16% ± 0.3% versus 14.5% ± 3.35%; p = 0.133; [Figures 1](#fig1){ref-type="fig"}A and 1B), from baseline to D5 of FSGS (6.16% ± 0.3% versus 20.99% ± 2.20%; p = 0.001; [Figures 1](#fig1){ref-type="fig"}A and 1C), from D5 to D14 of FSGS (20.99% ± 2.20% versus 33.63% ± 7.3%; p = 0.001; [Figures 1](#fig1){ref-type="fig"}C and 1D), and from baseline to D28 of FSGS (6.16% ± 0.3% versus 26.5% ± 5.24%; p \< 0.0001; [Figures 1](#fig1){ref-type="fig"}A and 1E).Figure 1WT1 Increases in Renin-Stained Cells in the Juxta-Glomerular Compartment Following Podocyte Depletion in the Cytotoxic Anti-podocyte Antibody Model of FSGSConfocal microscopy images marked (A--E) show the merge for WT1 (green), renin (red), collagen IV (blue), and DAPI (gray). Collagen IV demarcates glomeruli. Insets show the JGC for each channel, labeled as superscripts. Scale bars, 20 μm.(A) Baseline (n = 5), WT1 (A1) is limited to podocytes and not detected in renin-stained cells (A2).(B) D3 (n = 5), WT1 (B1) is detected in the cytoplasm of renin-stained cells (B2).(C) D5 (n = 5), WT1 (C1) increases in JGC, overlapping with renin (C2), creating a yellow color.(D) D14 (n = 5), renin-stained cells (D2) co-staining with WT1 (D1) increase in the JGC.(E) D28 (n = 8), WT1 (E1) and renin (E2) co-staining persists.(F) Quantitation of the percentage of renin-stained cells in the JGC co-staining for WT1.

Podocyte loss in podocyte TGFβ-Receptor1 transgenic (*PodTgfbr1*) mice ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C) and membranous nephropathy rats (passive Heymann nephritis \[PHN\] model) ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E) was also accompanied by increased WT1 in renin-stained JGC cells. In contrast, WT1 was not detected in renin cells post uninephrectomy in mice, where absolute podocyte number remained normal ([Figure S1](#mmc1){ref-type="supplementary-material"}F).

We confirmed the experimental results in human diseases. In normal human kidney, WT1 was mostly limited to podocytes ([Figure 2](#fig2){ref-type="fig"}A). However, *de novo* WT1 was detected in renin-stained JGC cells in human FSGS ([Figure 2](#fig2){ref-type="fig"}B) and membranous nephropathy ([Figure 2](#fig2){ref-type="fig"}C). Similar results were obtained with different WT1 antibodies, and no staining was detected when the primary antibody was omitted (not shown).Figure 2WT1 Increases in Renin-Stained Cells in the JGC in Human FSGS and Membranous NephropathyConfocal microscopy for WT1, renin, and DAPI in human kidneys. Insets show the JGC for each channel: WT1 (1, green), renin (2, red), DAPI (3, blue), and merged (4, yellow). Scale bars, 20 μm.(A) Normal human kidney (n = 5), WT1 is limited to podocytes (A1), and not detected in renin-stained cells (A2), hence no merge (A4).(B) Human FSGS (n = 5), WT1 in the JGC (B1) overlaps with renin-stained cells (B2) creating a yellow color (B4).(C) Human membranous nephropathy (n = 5), WT1 (C1) and renin in the JGC (C2) produce a yellow color (C4).

These results show that WT1 protein increases in renin-stained cells in the JGC in both experimental and human FSGS and membranous nephropathy in the context of podocyte loss.

Selective Deletion of WT1 in Cells of Renin Lineage Has No Impact on Podocytes or Kidney Function under Non-diseased Conditions {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------------

To test if *de novo* expression of WT1 in CoRL has relevance for their progenitor role to replace lost podocytes, *RenCreER tdTomato* mice ([@bib47], [@bib49]) were crossed with *Wt1*^*fl/fl*^ mice ([@bib38], [@bib12]) to generate *RenCreER tdTomato Wt1*^*fl/fl*^ mice (abbreviated *RenWt1*^*fl/fl*^) so that WT1 could be conditionally and selectively deleted in tdTomato-labeled CoRL ([Figure S2](#mmc1){ref-type="supplementary-material"}). CoRL and their descendants permanently express tdTomato dependent on Cre-mediated recombination, which allows lineage tracing of CoRL. Glomerular cells do not ectopically express renin (and hence Cre) under injury conditions. *RenCreER tdTomato Wt1*^*+/+*^ (abbreviated *RenWt1*^*+/+*^) served as controls, where tdTomato was expressed in CoRL but WT1 remained ([Figures S2](#mmc1){ref-type="supplementary-material"}A, S2F, and S2H). Genotyping discerned the lox and wild-type *Wt1* alleles ([Figure S2](#mmc1){ref-type="supplementary-material"}A1), and a flox deletion primer distinguished *RenWt1*^*fl/fl*^ mice given tamoxifen versus corn oil ([Figure S2](#mmc1){ref-type="supplementary-material"}A2). Following tamoxifen, *Wt1* mRNA from RFP^+^CoRL isolated using laser capture microscopy was significantly lower in *RenWt1*^*fl/fl*^ compared with *RenWt*^*+/+*^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}B), while *renin* mRNA levels were similar ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Cre was restricted to the JGC in mice containing the *CreER* transgene but not in Cre-negative mice ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). TdTomato, detected without the use of an antibody, confirmed similar CoRL labeling efficiency in *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice given tamoxifen ([Figures S2](#mmc1){ref-type="supplementary-material"}F and S2G). tdTomato was absent in *RenCre*-negative mice (not shown). Ninety-five percent of renin^+^ CoRL stained with red fluorescent protein (RFP) antibody, which detected tdTomato in *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice (not shown). Mice that did not report were excluded, accounting for \<1% of all mice given tamoxifen. At baseline, WT1 was in a typical podocyte distribution in *RenWt1*^*fl/fl*^ mice, indistinguishable from *RenWt1*^*+/+*^ mice, proving deletion in CoRL had no impact on podocytes ([Figures S2](#mmc1){ref-type="supplementary-material"}H and S2I). WT1 was detected in \<5% of CoRL in non-diseased *RenWt1*^*+/+*^ mice but was not detected in CoRL in non-diseased *RenWt1*^*fl/fl*^ mice ([Figures S2](#mmc1){ref-type="supplementary-material"}H and S2I). These results show that *Wt1* mRNA and WT1 protein were selectively reduced in tdTomato^+^ CoRL of *RenWt1*^*fl/fl*^ but not in *RenWT*^*+/+*^ mice, with no consequences on podocyte health under normal conditions.

Increased WT1 Was Not Seen in JGC of Wt1 Conditional Knockout Mice Following Podocyte Depletion {#sec2.3}
-----------------------------------------------------------------------------------------------

WT1 overlap with RFP^+^ was not present in the vast majority of CoRL in the JGC in normal *RenWt1*^*+/+*^and *RenWt1*^*fl/fl*^ mice (7 ± 2.5 versus 5.6 ± 2.0, respectively; p = 0.99; [Figures 3](#fig3){ref-type="fig"}A, 3D, and 3G). In *RenWt1*^*+/+*^ mice at D28 following podocyte loss, RFP^+^CoRL in the JGC co-stained with WT1 increased compared with baseline (103 ± 12.36 versus 7 ± 2.5; p \< 0.001; [Figures 3](#fig3){ref-type="fig"}B and 3G). By contrast, in *RenWt1*^*fl/fl*^ mice at D28, only 5.8 ± 1.8 of RFP^+^ CoRL in the JGC co-stained with WT1 ([Figures 3](#fig3){ref-type="fig"}E and 3G). Because enalapril increases RFP^+^CoRL in the JGC ([@bib35]), *RenWt1*^*+/+*^ mice were given enalapril for 25 days following podocyte loss. RFP^+^CoRL in the JGC co-expressing WT1 further increased at D28 following enalapril compared with baseline (419.5 ± 117.79 versus 7 ± 2.5; p \< 0.0001; [Figures 3](#fig3){ref-type="fig"}A, 3C, and 3G). An increase in WT1 expression was not observed in JGC of *RenWt1*^*fl/fl*^ mice after enalapril ([Figures 3](#fig3){ref-type="fig"}F and 3G). Similarly, the number of RFP^+^WT1^−^CoRL increased in *RenWt1*^*+/+*^ mice following podocyte depletion ([Figures S3](#mmc1){ref-type="supplementary-material"}B, S3C), while the number of RFP^+^WT1^−^CoRL in *RenWt1*^*fl/fl*^ mice did not increase ([Figures S3](#mmc1){ref-type="supplementary-material"}E, S3F).Figure 3WT1 Does Not Increase in CoRL in *RenWt1*^*fl/fl*^ Mice Following Podocyte Depletion in the Cytotoxic Anti-podocyte Antibody Model of FSGSConfocal microscopy for WT1 (green), RFP (red), collagen IV (blue), and DAPI (gray) in FSGS in *RenWt1*^*+/+*^ (A--C) and *RenWt1*^*fl/fl*^ (D--F) mice. Insets show the JGC for each channel, labeled as superscripts. Scale bars, 20 μm.(A--C) *RenWt1*^*+/+*^ mice. (A) At baseline WT1 is limited to podocytes (A1); RFP is limited to the JGC (A2). (B) At D28, WT1 (B1) merges with RFP (B2) in the JGC, creating a yellow color. WT1 is reduced in glomeruli. (C) At D28, after 25 days of enalapril, WT1 (C1) and RFP (C2) are increased in the JGC.(D--F) *RenWt1*^*fl/fl*^ mice. (D) At baseline, WT1 (D1) is limited to podocytes; RFP (D2) is limited to JGC. (E) At D28, WT1 is reduced in podocytes, and not detected (E1) in RFP^+^ cells (E2) in the JGC. (F) At D28, after 25 days of enalapril, there is no WT1(F1) in RFP^+^ cells (F2).(G) Stacked bar graph shows the number of RFP^+^CoRL not expressing WT^−^ (red) and co-expressing WT1^+^ (green) in the JGC. RFP^+^WT1^+^ cells increase progressively in diseased *RenWt1*^*+/+*^ but not in *RenWt1*^*fl/fl*^ mice (n = 13/group).

These results show the following: (1) although WT1 was not detected in the majority of cells in the JGC under normal conditions, the number of RFP^+^CoRL co-expressing WT1 increases progressively following podocyte loss in *RenWt1*^*+/+*^ mice; (2) WT1 did not increase in RFP^+^CoRL in diseased *RenWt1*^*fl/fl*^ mice, consistent with successful targeted ablation of WT1 in CoRL; (3) enalapril increased the number of CoRL co-expressing WT1 in *RenWt1*^*+/+*^ mice following podocyte loss but not in *RenWt1*^*fl/fl*^ mice.

CoRL Migration to the Glomerulus Is Reduced in *RenWt1*^*fl/fl*^ Mice Following Podocyte Depletion {#sec2.4}
--------------------------------------------------------------------------------------------------

Triple staining was performed for p57 (podocytes), RFP (tdTomato^+^, CoRL), and collagen IV (demarcates glomeruli) to determine if deleting WT1 reduced CoRL migration from the JGC to the glomerulus following abrupt podocyte loss. RFP^+^CoRL were rarely detected in glomeruli at baseline of either *RenWt1*^*+/+*^ or *RenWt1*^*fl/fl*^ mice ([Figures 4](#fig4){ref-type="fig"}A, 4D and 4G). At D28 FSGS in *RenWt1*^*+/+*^ mice, RFP^+^CoRL were detected in 3.5% ± 2.4% of glomeruli compared with baseline (0.43% ± 0.2%; p = 0.013; [Figures 4](#fig4){ref-type="fig"}B and 4G). At D28 FSGS in *RenWt1*^*fl/fl*^ mice, RFP^+^CoRL were barely detected in glomeruli compared with *RenWt1*^*+/+*^ mice (p = 0.001; [Figures 4](#fig4){ref-type="fig"}E and 4G). Consistent with our recent report ([@bib35]), administering enalapril to *RenWt1*^*+/+*^ mice following podocyte depletion increased the migration of RFP^+^CoRL to 12.95% ± 3.07% of glomeruli compared with untreated (p \< 0.001; [Figures 4](#fig4){ref-type="fig"}C and 4G). However, enalapril had little impact on RFP^+^CoRL migration to glomeruli in *RenWt1*^*fl/fl*^ mice ([Figures 4](#fig4){ref-type="fig"}F and 4G). Staining for renin and Cre was not detected in glomerular cells in disease, consistent with CoRL migration to the glomerulus rather than ectopic renin expression in disease. These results were similar to our previous reports ([@bib47]).Figure 4RFP^+^CoRL Migration to the Glomerulus Is Significantly Reduced in Diseased *RenWt1*^*fl/fl*^ Mice Compared with Diseased *RenWt1*^*+/+*^ MiceConfocal microscopy for p57 (green, podocytes), RFP (red, CoRL), collagen IV (blue, demarcates glomerulus), and DAPI (gray, nucleus). Insets show the glomerulus marked with a white box, labeled as superscripts. Scale bars, 20 μm.(A--C) *RenWt1*^*+/+*^ mice. (A, A1) In baseline *RenWt1*^*+/+*^ mice, RFP^+^CoRL (solid arrows) are restricted to the JGC and p57 to podocytes. (B, B1) A serial biopsy at D28 in the same *RenWt1*^*+/+*^ mouse from (A). RFP^+^CoRL are in glomeruli (dashed arrows). (C, C1) At FSGS D28 after enalapril, RFP^+^CoRL in both the JGC and glomeruli are further increased and a subset in the tuft *de novo* express the podocyte marker p57 (arrowheads).(D--F) *RenWt1*^*fl/fl*^ mice. (D, D1) In baseline *RenWt1*^*fl/fl*^ mice, RFP^+^CoRL (solid arrows) are restricted to the JGC and p57 to podocytes. (E, E1) At D28, despite the decrease in p57 (podocytes), RFP^+^CoRL remain restricted to the JGC (arrow). (F, F1) At D28 after enalapril, RFP^+^CoRL were mostly limited to the JGC.(G) Quantitation of the percentage of glomeruli with RFP^+^CoRL increased progressively in diseased *RenWt1*^*+/+*^ mice but not in diseased *RenWt1*^*fl/fl*^ mice (n = 13/group).

[Figures S4](#mmc1){ref-type="supplementary-material"} and [4](#fig4){ref-type="fig"}C show that once RFP^+^CoRL migrated from the JGC to the glomerulus, a subset *de novo* co-express podocyte markers P57 ([Figure 4](#fig4){ref-type="fig"}C) podocin ([Figure S4](#mmc1){ref-type="supplementary-material"}A--S4A4) and synaptopodin ([Figure S4](#mmc1){ref-type="supplementary-material"}B--S4B4), consistent with CoRL transdifferentiating toward a podocyte fate.

These results show that WT1 is critical for CoRL migration to the glomerulus following podocyte loss and their transdifferentiation. In the absence of WT1, enalapril has reduced efficacy on CoRL migration and transdifferentiation.

WT1 Is Important for CoRL Proliferation Following Podocyte Depletion {#sec2.5}
--------------------------------------------------------------------

To test the role of WT1 in CoRL proliferation, bromodeoxyuridine (BrdU) was administered via intraperitoneal injections every 48 hr, starting at D2. Triple staining was performed for BrdU, WT1, and RFP to determine if proliferation was restricted to RFP^+^CoRL that co-expressed WT1, and if WT1 is necessary for CoRL proliferation? BrdU was absent in RFP^+^CoRL at baseline in *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice ([Figures 5](#fig5){ref-type="fig"}A, 5D, and 5G). This was not a false negative, as BrdU was detected in neighboring tubules. Following podocyte depletion in *RenWt1*^*+/+*^ mice, BrdU increased in RFP^+^WT1^+^ cells compared with baseline (25.8 ± 9.2 versus 0.8 ± 0.5; p \< 0.01; [Figures 5](#fig5){ref-type="fig"}B and 5G). In contrast, BrdU was barely detected in RFP^+^CoRLs in *RenWt1*^*fl/fl*^ mice ([Figures 5](#fig5){ref-type="fig"}E and 5G). In enalapril-treated *RenWt1*^*+/+*^ FSGS mice, RFP^+^WT1^+^BrdU^+^ cells in the JGC increased compared with untreated mice (131.3 ± 51.7 versus 25.8 ± 9.2; p = 0.0001; [Figures 5](#fig5){ref-type="fig"}C and 5G). In enalapril-treated *RenWt1*^*fl/fl*^ FSGS mice, RFP^+^WT1^+^BrdU^+^ cells did not increase ([Figures 5](#fig5){ref-type="fig"}F and 5G). To test WT1 independent proliferation, we counted RFP^+^BrdU^+^WT1^−^ cells. BrdU was only observed in a small portion of RFP^+^WT1^−^ cells in *RenWt1*^*+/+*^ FSGS mice compared with baseline (5 ± 0.8 versus 0.3 ± 0.5; p \< 0.05; [Figures 5](#fig5){ref-type="fig"}B, 5C, and 5G).Figure 5RFP^+^CoRL Proliferation Is Significantly Reduced in Diseased *RenWt1*^*fl/fl*^ Mice Compared with Diseased *RenWt1*^*+/+*^ MiceConfocal microscopy for BrdU (blue), WT1 (green), RFP (red), and DAPI (gray) in experimental FSGS in *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice. Insets show the JGC for each channel, labeled as superscripts. Scale bars, 20 μm.(A--C) *RenWt1*^*+/+*^*mice.* (A) At baseline, a BrdU^+^ cell (A1) is detected in the adjacent tubule. BrdU is not detected in the JGC. WT1 (A2) is not detected in RFP^+^ cells (A3). (B) At FSGS D28, BrdU (B1) co-localizes with WT1 (B2) and RFP (B3), creating a white/purple color (B5, solid arrows). A few BrdU^+^ cells do not express WT1 (B1-B5, dashed arrow) (C) At D28 after enalapril, BrdU^+^ (C1), WT1^+^ (C2), RFP^+^ (C3) cells increase (C5, solid arrows). A few BrdU^+^ cells do not express WT1 (C1--C5, dashed arrow).(D--F) *RenWt1*^*fl/fl*^ mice. (D) At baseline, neither BrdU (D1) nor WT1 (D2) is detected in RFP^+^ (D3) cells in the JGC. (E) At D28, a BrdU^+^ cell (E1, solid arrow) is detected in the adjacent tubule and does not overlap with WT1 (E2) or RFP (E3), hence no merge (E5). (F) At D28 after enalapril, a BrdU^+^ cell (F1, solid arrow) does not overlap with WT1 (F2) or RFP (F3), hence no merge (F5).(G) Stacked bar graph shows the number of RFP^+^BrdU^+^WT1^−^ (blue) and RFP^+^BrdU^+^WT1^+^ (green) cells in the JGC. RFP^+^BrdU^+^WT1^+^ cells increase progressively in diseased *RenWt1*^*+/+*^ mice but not in *RenWt1*^*fl/fl*^ mice (n = 13/group).

Triple staining was also performed for the proliferation marker Ki67, WT1, and RFP ([Figure S7](#mmc1){ref-type="supplementary-material"}). Ki67 was not detected in RFP^+^CoRL at baseline in *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7D) but was detected in neighboring tubules. Following podocyte depletion, Ki67 increased in RFP^+^ WT1^+^CoRL ([Figure S7](#mmc1){ref-type="supplementary-material"}B), which was augmented by enalapril ([Figure S7](#mmc1){ref-type="supplementary-material"}C). In *RenWt1*^*fl/fl*^ mice, Ki67 was barely detected in RFP^+^CoRL ([Figures S7](#mmc1){ref-type="supplementary-material"}E and S7F).

These results show that after podocyte depletion, the following occurs: (1) proliferation (BrdU ^+^ or Ki67^+^) of CoRL (RFP^+^) occurs in cells co-expressing WT1; (2) CoRL proliferation was reduced in *RenWt1*^*fl/fl*^ mice; (3) enalapril increased CoRL proliferation in diseased *RenWt1*^*+/+*^ but not in *RenWt1*^*fl/fl*^ mice.

Following Podocyte Loss, CoRL that Migrate to the Glomerulus Lose Mesenchymal Markers and *De Novo* Acquire Epithelial Markers {#sec2.6}
------------------------------------------------------------------------------------------------------------------------------

CoRL and podocytes derive from mesenchymal lineages ([@bib4], [@bib29], [@bib9], [@bib36]). To determine if WT1 in CoRL is necessary for changes in mesenchymal and epithelial cell markers, and if these changes were augmented by enalapril, additional studies were performed ([Figures 6](#fig6){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}). Staining for the mesenchymal marker myosin heavy chain 11 (MYH11) was detected in 90% ± 7.5% and 84.1% ± 8.2% of RFP^+^CoRL in the JGC in baseline *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice, respectively ([Figures 6](#fig6){ref-type="fig"}A, 6D, and 6G). Following podocyte depletion in *RenWt1*^*+/+*^ mice, the percentage of MYH11^+^RFP^+^ cells decreased to 67.5% ± 5.3% compared with baseline (p = 0.0059; [Figures 6](#fig6){ref-type="fig"}B and 6G). The percentage of MYH11^+^RFP^+^ cells did not decrease in *RenWt1*^*fl/fl*^ mice with FSGS compared with baseline (82.6% ± 10.6% versus 84.1% ± 8.2%; p = 0.99; [Figures 6](#fig6){ref-type="fig"}E and 6G). In enalapril-treated FSGS *RenWt1*^*+/+*^ mice, MYH11^+^ RFP^+^CoRL decreased (44.3% versus 67.5%; p = 0.008; [Figures 6](#fig6){ref-type="fig"}C and 6G). Giving enalapril to *RenWt1*^*fl/fl*^ mice did not reduce MYH11^+^RFP^+^CoRL (78.7% versus 82.6%; p \> 0.99; [Figures 6](#fig6){ref-type="fig"}F and 6G). CoRL that migrated to glomeruli did not stain for MYH11 with either strain (data not shown).Figure 6RFP^+^CoRL MET Is Significantly Reduced in Diseased *RenWt1*^*fl/fl*^ Mice Compared with Diseased *RenWt1*^*+/+*^ MiceConfocal microscopy for myosin11 (MYH11, green, mesenchymal marker), RFP (red, CoRL), and DAPI (blue, nuclei) in the JGC (A--F). Insets show each channel, labeled as superscripts. Scale bars, 20 μm.(A--C) *RenWt1*^*+/+*^ mice. (A) At baseline, MYH11 (A1) merges with RFP (A2) in the JGC, creating a yellow color. (B) At FSGS D28, MYH11 (B1) decreases in RFP^+^ (B2) cells. (C) At D28 after enalapril, MYH11 (C1) decreases, despite an increase in RFP^+^ cells (C2).(D--F) *RenWt1*^*fl/fl*^ mice. (D) At baseline, MYH11 (D1) merges with RFP (D2). (E) At FSGS D28, MYH11 (E1) in RFP^+^ cells (E2, solid arrows) persists. (F) At D28 after enalapril, MYH11 (F1) in RFP^+^ cells (F2, solid arrows) also persists.(G) The percentage of RFP^+^CoRL expressing MYH11 decreases in *RenWt1*^*+/+*^ mice with FSGS and is augmented by enalapril. *RenWt1*^*fl/fl*^ mice show no significant decrease in MYH11 (n = 13/group).(H--M) Confocal microscopy for cytokeratin 18 (CK18, green, epithelial marker), RFP (red, CoRL), and DAPI (blue, nuclei) in the JGC (H--M). Insets show each channel, labeled as superscripts. Scale bars, 20 μm.(H--J) *RenWt1*^*+/+*^ mice. (H) At baseline, CK18 (H1) is barely detected in RFP^+^ cells (H2). (I) At FSGS D28, CK18 (I1) increases in RFP^+^ cells (I2), creating a yellow color (solid arrows). (J) At D28 after enalapril, CK18 (J1) further increases in RFP^+^ cells (J2), creating a yellow color (solid arrows).(K--M) *RenWt1*^*fl/fl*^ mice. (K) At baseline, CK18 (K1) is not detected in RFP^+^ cells (K2). At FSGS D28 (L) and after enalapril (M), CK18 (L1, M1) does not increase in RFP^+^ cells (L2, M2).(N) The percentage of RFP^+^CK18^+^cells increases in diseased *RenWt1*^*+/+*^ mice, which is augmented by enalapril. CK18 does not increase significantly in diseased *RenWt1*^*fl/fl*^ mice (n = 13/group).

In RFP^+^CoRL in the JGC, the epithelial cell marker cytokeratin 18 (CK18) was barely detected at baseline in either *RenWt1*^*+/+*^ or *RenWt1*^*fl/fl*^ mice ([Figures 6](#fig6){ref-type="fig"}H, 6K, and 6N). At D28 FSGS in *RenWt1*^*+/+*^ mice, the percentage of RFP^+^CK18^+^CoRL in the JGC increased compared with baseline (16.8% ± 2.4% versus 1.5% ± 0.9%; p \< 0.0001; [Figures 6](#fig6){ref-type="fig"}I and 6N). The percentage of RFP^+^CK18^+^CoRL was further increased by enalapril compared with baseline (27.25% ± 6.08% versus 16.75% ± 2.36%; p \< 0.0001; [Figures 6](#fig6){ref-type="fig"}J and 6N). In contrast, in *RenWt1*^*fl/fl*^ mice, the percentage of RFP^+^CK18^+^CoRL did not increase (2.8% ± 3.5% versus 1.5% ± 0.8%; p = 0.606; [Figures 6](#fig6){ref-type="fig"}K, 6L, and 6N), and enalapril had no impact (3.7% ± 3.1% versus 2.8% ± 3.5% versus FSGS without enalapril; p \> 0.99) ([Figures 6](#fig6){ref-type="fig"}K, 6M, and 6N).

[Figure S6](#mmc1){ref-type="supplementary-material"} confirms these results using additional mesenchymal and epithelial cell markers. The mesenchymal markers αSMA ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6F) and smooth muscle protein 22 (SM22) ([Figures S6](#mmc1){ref-type="supplementary-material"}G--S6L) were abundant in RFP^+^CoRL in the JGC at baseline in both strains ([Figures S6](#mmc1){ref-type="supplementary-material"}A, S6D, S6G, and S6J). Co-staining for both mesenchymal markers decreased in *RenWt1*^*+/+*^ mice with FSGS ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6H), and was further decreased by enalapril ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6I). No RFP^+^CoRL in glomeruli co-expressed αSMA or SM22 ([Figures 6](#fig6){ref-type="fig"}A and 6C). In contrast, αSMA^+^/RFP^+^CoRL and SM22^+^/RFP^+^CoRL did not decrease in *RenWt1*^*fl/fl*^ mice with FSGS, or with enalapril ([Figures S6](#mmc1){ref-type="supplementary-material"}E, S6F, S6K, and S6L).

The epithelial cell marker E-cadherin was not detected in RFP^+^ cells in the JGC at baseline in either *RenWt1*^*+/+*^ or *RenWt1*^*fl/fl*^ mice ([Figures S6](#mmc1){ref-type="supplementary-material"}M and S6P). Following podocyte depletion in *RenWt1*^*+/+*^ mice, RFP^+^ cells in the JGC *de novo* expressed E-cadherin, which was augmented by enalapril ([Figures S6](#mmc1){ref-type="supplementary-material"}N and S6O). In contrast, E-cadherin staining was not detected in the JGC in *RenWt1*^*fl/fl*^ mice following podocyte depletion, and enalapril had no effect ([Figures S6](#mmc1){ref-type="supplementary-material"}Q and S6R).

Following podocyte depletion in *RenWt1*^*+/+*^ mice, a subset of CoRL that migrated from the JGC ([Figures S5](#mmc1){ref-type="supplementary-material"}A1--S5A4, S5B1--S5B4, and S5C1--S5C4) to the glomerular tuft no longer expressed αSMA ([Figure S5](#mmc1){ref-type="supplementary-material"}A5--S5A8). There was *de novo* expression in CoRL in glomeruli of the epithelial markers E-cadherin ([Figure S5](#mmc1){ref-type="supplementary-material"}B5--S5B8) and cytokeratin 18 ([Figure S5](#mmc1){ref-type="supplementary-material"}C5--S5C8), coincident with loss of mesenchymal markers.

These results show that following abrupt podocyte depletion, mesenchymal markers (MYH11, αSMA, SM22) decrease in CoRL, coincident with *de novo* staining for the epithelial cell markers cytokeratin 18 and E-cadherin ([Figure S6](#mmc1){ref-type="supplementary-material"}S). These events were augmented by enalapril in *RenWt1*^*+/+*^ mice, supporting the notion that CoRL undergo MET in *RenWt1*^*+/+*^ mice with FSGS, but these events are significantly reduced when WT1 is deleted.

Podocyte Replacement Is Lower in Diseased *RenWt1*^*fl/fl*^ Mice {#sec2.7}
----------------------------------------------------------------

The binding of the podocyte-depleting antibody was similar in *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice ([Figures S2](#mmc1){ref-type="supplementary-material"}J and S2K). Podocyte density, measured by quantitating p57, was similar at baseline in *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice ([Figures 7](#fig7){ref-type="fig"}A, 7B, and 7E). Podocyte density decreased in *RenWt1*^*+/+*^ mice with FSGS compared with baseline (185.2 ± 17.1 × 10^6^ versus 250.7 ± 10.0 × 10^6^ podocytes/μm^3^ glomerular tuft volume; p \< 0.0001; [Figures 7](#fig7){ref-type="fig"}C and 7E). Moreover, podocyte density was significantly lower in diseased *RenWt1*^*fl/fl*^ mice compared with diseased *RenWt1*^*+/+*^ mice (109.3 ± 10.09 × 10^6^ versus 185.2 ± 17.1 × 10^6^ podocytes/μm^3^; p \< 0.001; [Figures 7](#fig7){ref-type="fig"}D and 7E). Similar findings were shown for podocin ([Figures 7](#fig7){ref-type="fig"}G--7J). Glomerulosclerosis increased in diseased *RenWt1*^*+/+*^ mice but was significantly higher in diseased *RenWt1*^*fl/fl*^ mice ([Figure 7](#fig7){ref-type="fig"}F). The urinary albumin to creatinine ratio was also significantly higher in diseased *RenWt1*^*fl/fl*^ mice ([Figure 7](#fig7){ref-type="fig"}K). In summary, podocyte density was lower in *RenWt1*^*fl/fl*^ mice compared with *RenWt1*^*+/+*^ mice, accompanied by higher glomerulosclerosis and albuminuria.Figure 7Podocyte Depletion in the Cytotoxic Anti-podocyte Antibody Model of FSGS Is Higher in Diseased *RenWt1*^*fl/fl*^ Mice than in Diseased *RenWt1*^*+/+*^ Mice(A--F) Podocytes are identified by p57 (brown, nuclear, arrows) and matrix (pink) in a baseline biopsy from *RenWt1*^*+/+*^ (A) and *RenWt1*^*fl/fl*^ (B) mice, and a serial biopsy in the same mice at FSGS D28 (C and D). (E) Podocyte density was similar at baseline but lower in diseased *RenWt1*^*fl/fl*^ compared with diseased *RenWt1*^*+l+*^*mice.* (F) Glomerulosclerosis is higher in diseased *RenWt1*^*fl/fl*^ compared with diseased *RenWt1*^*+/+*^ mice.(G--J) Podocin staining (green) is similar in healthy podocytes in baseline *RenWt1*^*+/+*^ (G) and *RenWt1*^*fl/fl*^ (H) mice. Podocin decreases at FSGS D28 in *RenWt1*^*+/+*^ mice (I) and is more pronounced in diseased *RenWt1*^*fl/fl*^ mice (J). Scale bars, 20 μm.(K) Urinary albumin to creatinine ratio in *RenWt1*^*fl/fl*^ mice (dark bars) is higher than *RenWt1*^*+/+*^ mice (light bars) (n = 13/group).

Discussion {#sec3}
==========

Adult podocytes cannot proliferate and are unable to self-renew following depletion ([@bib2], [@bib44]). Their replacement in glomerular diseases is reliant on progenitors ([@bib52], [@bib56]). CoRL plasticity has been reported in podocytes, PECs, kidney pericytes, and mesangial cells ([@bib18], [@bib49], [@bib57], [@bib27], [@bib60]). To serve as progenitors for podocytes, CoRL must increase in number, migrate from the JGC to the glomerulus, and reprogram from a mesenchymal to an epithelial fate. To better understand the mechanisms underlying these events, we selectively genetically deleted WT1 in CoRL in transgenic mice. Reducing podocytes with a cytopathic anti-podocyte antibody resulted in a significant reduction in CoRL proliferation, migration, and MET, suggesting a critical role for WT1.

We show that WT1 staining is detected in \<5%--7% of renin-expressing cells in the JGC in normal mice and rats, and only occasionally in the JGC in normal human kidneys, similar to previous reports ([@bib50]). The first major result of the studies was that following podocyte depletion in three experimental models, WT1 increased up to 5.5-fold from baseline in renin-expressing cells in the JGC. WT1 also increased in renin-expressing cells in human FSGS and membranous nephropathy. WT1 did not increase following uninephrectomy, serving as a negative control because podocyte number was unchanged.

The role for WT1 is well described in podocyte health ([@bib43], [@bib40]), in non-kidney cell transdifferentiation ([@bib23]), and progenitor function ([@bib38], [@bib1]). To test the hypothesis that WT1 is necessary for CoRL to function as podocyte progenitors, we generated a transgenic mouse where WT1 was inducibly deleted specifically in CoRL. Under non-stressed conditions, deleting WT1 in CoRL had no impact on kidney or podocyte function and morphology.

CoRL migrate from the JGC to the glomerulus or tubulo-interstitium during kidney development and in disease ([@bib55], [@bib47], [@bib49], [@bib57], [@bib70], [@bib35]). Here, RFP^+^CoRL were rarely detected in glomeruli of non-diseased *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice. However, RFP^+^CoRL were readily detected in glomeruli in *RenWt1*^*+/+*^ mice following podocyte depletion, similar to previous reports ([@bib47], [@bib35]). The second major finding was that following podocyte depletion, RFP^+^CoRL were barely detected in glomeruli of *RenWt1*^*fl/fl*^ mice, and migration to the glomerulus was not augmented by enalapril in *RenWt1*^*fl/fl*^ mice. These results are consistent with WT1 being necessary for CoRL migration and the enhanced migratory effects of enalapril. Similar results in the cancer field suggest that WT1 enhances cell invasion and migration ([@bib24], [@bib5]).

CoRL increase in the JGC following podocyte depletion ([@bib47], [@bib48]), increased glomerular volume ([@bib21]), hypotension ([@bib6]), and following angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers ([@bib35]). BrdU and Ki67 staining showed that following podocyte depletion in *RenWt1*^*+/+*^ mice, RFP^+^CoRL proliferated, which was augmented by enalapril ([@bib13], [@bib35]). A third major finding was no increase in CoRL proliferation in *RenWt1*^*fl/fl*^ mice, and enalapril had no effect. This was of interest, as several groups have shown that WT1 enhances proliferation of tumor cells and cardiac endothelial cells ([@bib34], [@bib68]).

Like podocytes ([@bib4], [@bib29]), CoRL derive from mesenchymal origins ([@bib54], [@bib39], [@bib65], [@bib8]). To become podocytes, CoRL need to decrease mesenchymal proteins and acquire epithelial and podocyte proteins. At baseline, RFP^+^CoRL in the JGC in both *RenWt1*^*+/+*^ and *RenWt1*^*fl/fl*^ mice express mesenchymal markers (MYH11, αSMA, SM22) but not epithelial markers (cytokeratin 18, E-cadherin). Following podocyte depletion in *RenWt1*^*+/+*^ mice, RFP^+^CoRL in the JGC expressing these mesenchymal markers decreased significantly. This coincided with the *de novo* expression of cytokeratin 18 and E-cadherin. The MET-like changes in diseased *RenWt1*^*+/+*^ mice were augmented by enalapril. When in the glomerulus, a subset of CoRL co-expressed the podocyte markers p57, podocin, and synaptopodin. The fourth major finding was that following podocyte depletion in *RenWt1*^*fl/fl*^ mice, mesenchymal markers in RFP^+^ CoRL did not decrease, nor did they begin to express epithelial markers, and enalapril had no impact.

These findings are consistent with our previous reports on the importance of disruption of MET underlying the origin of Wilms\' tumors ([@bib3], [@bib22]), the role of *Wt1* in this MET programming ([@bib11], [@bib15]), and that loss of WT1 blocks MET in the cap mesenchyme ([@bib15]).

The fifth major finding was that following abrupt podocyte loss, podocyte density remained lower in diseased *RenWt1*^*fl/fl*^ compared with diseased *RenWt1*^*+/+*^mice, accompanied by more glomerular scarring and albuminuria. We recognize that CoRL transdifferentiation alone is not sufficient to explain the differences, and other factors including different kidney progenitor populations need to be considered.

Finally, our observation of intra-glomerular CoRL with coincident downregulation of renin expression would be consistent with the negative regulation previously described ([@bib58]). It will be of interest to assess the specific isoform(s) of WT1 expressed and retained in CoRL and the kinetics of renin downregulation and other cell differentiation features altered as a function of this interaction.

In summary, WT1 expression in CoRL is important for the glomerular response to damage. When WT1 is selectively deleted in CoRL in the setting of podocyte loss, their proliferation and migration to the glomerulus, and to some extent their transdifferentiation toward a podocyte fate through MET changes, are markedly reduced.

Experimental Procedures {#sec4}
=======================

*RenCreER tdTomato Wt1*^*+/+*^and *Wt1*^*fl/fl*^ Reporter Mice {#sec4.1}
--------------------------------------------------------------

*Ren1cCreERxRs-tdTomato-R* mice ([@bib47]) were crossed with a *Wt1* conditional knockout mouse (*Wt1*^*fl/fl*^) ([@bib38]). *Wt1* was inactivated in *RenCreER tdTomato Wt1*^*fl/fl*^ mice (abbreviated *RenWt1* ^*fl/fl*^) by administration of 100 mg/kg tamoxifen on four occasions. Mouse genotype was identified by PCR ([@bib38]). Kidney biopsies were performed to assess CoRL labeling as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. *RenWt1*^*fl/fl*^ and *RenWt1*^*+/+*^ were housed in the animal care facility of the University of Washington (UW) under specific pathogen-free conditions with food and water available ad libitum. These studies were reviewed and approved by the UW Institutional Animal Care and Use Committee (2968-04).

Experimental Models of Glomerular Disease Accompanied by Podocyte Depletion {#sec4.2}
---------------------------------------------------------------------------

The following experimental models of podocyte depletion were used:(1)A cytotoxic sheep anti-glomerular antibody model of experimental FSGS was induced in *RenWt1*^*fl/f*^ and *RenWt1*^*+/+*^mice as previously described ([@bib27], [@bib35]). On D3, when podocyte number was decreased by 30%--40%, mice were randomized into two groups: group 1 received drinking water; group 2 received the ACE inhibitor enalapril (75 mg/mL). Mice were killed on D28. Urine was collected at baseline, and on days 7, 14, and 28. Amersham Cell Proliferation Labeling Reagent (GE Healthcare Life Sciences, Little Chalfont, UK) was administered to quantitate cell proliferation ([@bib27]). Urines were collected for albumin measurements by radial immunodiffusion assay (RID) ([@bib37]); urine creatinine was measured by colorimetric micro-plate assay (Cayman Chemical Company, Ann Arbor, MI).(2)Podocyte TGFβ-Receptor1 transgenic (*PodTgfbr1*) mice given doxycycline underwent TGFβR1-induced podocyte apoptosis and loss of 25% (D7) and 40% (D14), accompanied by glomerulosclerosis ([@bib10]).(3)A PHN model of membranous nephropathy induced as previously described ([@bib42]) underwent progressive podocyte depletion ([@bib46]).(4)A uninephrectomy model served as a negative control for podocyte depletion ([@bib49]).

Human Glomerular Disease {#sec4.3}
------------------------

Kidney biopsies from patients with FSGS and membranous nephropathy were obtained from the University of Chicago (UC). The study protocol was approved by the UC Institutional Review Board. Further details are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Laser Capture Microscopy and qRT-PCR {#sec4.4}
------------------------------------

RFP^+^CoRL were isolated by LCM, as described ([@bib62]), with the Leica Laser Microdissection Systems LMD6500 and LMD7000 (Leica Microsystems Inc., Buffalo Grove, IL).

Immunoperoxidase and Immunofluorescent Staining {#sec4.5}
-----------------------------------------------

Formalin-fixed paraffin-embedded mouse, rat, and human kidney sections or frozen tissue sections (4--20 μm thick) were used. Following standard antigen retrieval steps, Avidin-biotin based, polymer-based, and fluorochrome-based staining was performed as previously described ([@bib28], [@bib64]). Further details are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Quantitative Analysis {#sec4.6}
---------------------

Absolute numbers of renin^+^, RFP^+^, WT1^+^, and RFP^+^/WT1^+^ expressing cells were counted in the JGC of fluorescence-stained sections. Results were expressed as a percentage of co-localized RFP^+^/WT1^+^ cells per number of renin^+^ cells. The percentage of proliferating (BrdU^+^) CoRL co-expressing WT1 in the JGC was measured by dividing the number of RFP^+^/WT1^+^/BrdU^+^-stained cells by the total number of RFP^+^ cells in the JGC. The total number of glomeruli and glomeruli with RFP^+^ cells were counted to determine the percentage of glomeruli with RFP^+^ cells. Absolute numbers of RFP^+-^, MYH11^+^, CK18^+^, MYH11^+^/RFP^+^, and CK18^+^/RFP^+^-expressing cells were counted in the JGC. Results were expressed as a percentage of MYH11^+^/RFP^+^ and CK18^+^/RFP^+^ cells per number of RFP^+^ cells in the JGC. Podocyte number was measured on 150 ± 20 glomeruli per animal on p57/periodic acid-Schiff-stained sections ([@bib70], [@bib35]).

Statistical Analysis {#sec4.7}
--------------------

Groups were compared using a one-way or two-way ANOVA for multiple comparisons with Bonferroni post hoc analysis with significant set at p \< 0.05. Data are presented as means ± SEM. All data were analyzed in GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA).

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S7Document S2. Article plus Supplemental Information

Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online at [http://dx.doi.org/10.1016/j.stemcr.2017.08.020](10.1016/j.stemcr.2017.08.020){#intref0010}.
